Gender-Affirming Hormone Therapy to Improved HIV Outcomes in Transgender and Gender-Diverse Populations

A study published in The Lancet HIV has found that gender-affirming hormone therapy (GAHT) is associated with improved HIV-related outcomes among transgender, nonbinary, and other gender-diverse individuals in the United States. The research highlights a connection between access to GAHT and better health indicators for these populations, who are disproportionately affected by HIV.

The findings suggest that GAHT may play a role in reducing the risk of HIV transmission and improving overall health outcomes for trans and gender-diverse people. Researchers examined data from various sources to assess the impact of hormone therapy on this group, focusing on its potential to address disparities in healthcare access and outcomes. The study emphasizes the importance of inclusive healthcare practices tailored to the needs of marginalized communities. Further details about the methodology or specific metrics were not disclosed in the summary provided.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Study Reveals Telemedicine Could Curtail Unnecessary Medical Testing Breakthrough in Ethylene Oxide Production Promises Lower Costs and Reduced Emissions Alzheimer’s Research: 16 New Susceptibility Genes Identified Funding Freeze Under Trump Administration Stalls Critical HIV Vaccine Research in Africa

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後